By Colin Kellaher
Medtronic PLC (MDT) on Monday said it named Sean Salmon executive vice president and president of its diabetes group.
The Dublin-based medical-technology company said Mr. Salmon succeeds Hooman Hakami, who is leaving Medtronic.
Mr. Salmon, who joined Medtronic in 2004, had been senior vice president and president of the coronary and structural heart business within the company's cardiac and vascular group. Medtronic said Mr. Salmon will serve on its executive committee.
Medtronic said Mr. Hakami, who had been executive vice president and president of the diabetes group since June 2014, will remain an adviser on an as-needed basis through February to assist with the transition.
The company said it still expects the diabetes group to post low-single-digit organic revenue growth in the current quarter. The group accounted for $592 million of the $7.5 billion of revenue Medtronic reported for the fiscal first quarter ended July 26.
Write to Colin Kellaher at email@example.com